| Literature DB >> 29250552 |
Marta Gamrot-Wrzoł1, Paweł Sowa1, Grażyna Lisowska1, Wojciech Ścierski1, Maciej Misiołek1.
Abstract
Sinonasal inverted papilloma is a relatively rare disease; however, it is prevalent enough for every ENT practitioner to encounter it several times throughout medical routines. Despite the developments in experimental and clinical medicine as well as surgical techniques, our knowledge of this disease is still inadequate. With improved imaging and better diagnostic techniques, proper diagnosis and qualification for surgical approaches leave no doubt. Although the endoscopic approach seems to be the gold standard for such condition, some cases may additionally require an external approach. Regardless of the type of surgery, postoperative management is crucial for both healing and long-term follow-up. Unfortunately, the procedures are still lacking in explicit and standardized postoperative management guidelines. Moreover, an important issue is still the need for a biomarker indicative of inverted papilloma and its malignant transformation. Several particles, within the spotlight of the researchers, have been SCCA, Ki-67, Bcl-2, Wnt proteins, and many more. Nevertheless, the topic requires further investigations.Entities:
Mesh:
Year: 2017 PMID: 29250552 PMCID: PMC5700512 DOI: 10.1155/2017/9195163
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Endoscopic image of inverted papilloma in the left nasal cavity. (A: nasal septum; B: left inferior nasal concha; the arrows indicate the inverted papilloma masses.).
Figure 2CT scan along the transverse (a) and frontal (b) plane in a patient with inverted papilloma of the nasal cavity and ethmoid cells at the left side; the arrows indicate focal hyperostosis.
Figure 3MR image along the transverse plane in a patient with left side (arrow) sinonasal inverted papilloma with visible tumor mass compression of the opposite side.
The Cannady classification [11].
| Localization | Recurrence rate | |
|---|---|---|
| A | Nasal cavity, ethmoid sinus, medial wall of the maxillary sinus | 3.0% |
| B | Other (than medial) walls of maxillary sinus, sphenoid sinus, frontal sinus | 19.8% |
| C | Extrasinus extension | 35.3% |
Factors elevating the risk of recurrence of inverted papilloma, as quoted by the literature available.
| Factor described | Publications |
|---|---|
| Young age of patients | Jardine et al., 2000 [ |
| Female sex | Suh et al., 1977 [ |
| Tobacco smoking | Roh et al., 2016 [ |
| Histopathological | |
| (i) Enhanced hyperkeratosis | Katori et al., 2006 [ |
| and presence of squamous hyperplasia | |
| (ii) Elevated mitotic index | |
| (iii) Lack of inflamed polyps | |
| (iv) Greater amount of aneuploid cells | Liu, 1990 [ |
Review of the literature on particles which may be potential biomarkers in the diagnosis of IP, recurrence, and malignant transformation.
| Particles evaluated | Potential role | Literature |
|---|---|---|
| Antigen Ki-67, | Elevated expression of antigen Ki-67 as a marker of malignant transformation of IP | Tsou et al., 2014 [ |
| Ki-67 may reflect activity of the tumor cells' proliferation and may be used to measure IP proliferation rate | Meng et al., 2014 [ | |
| Higher expression of Ki-67 antigen in IP than in an inflammatory condition | Mumbuc et al., 2007 [ | |
| Positive correlation of nuclear (noncytoplasmic) immunoexpression of survivin and antigen Ki-67 and oncoprotein Bcl-2 in both evaluated tumors: IP and SCC | Stasikowska-Kanicka et al., 2013 [ | |
| Immunoexpression of survivin, antigen Ki-67, and oncoprotein Bcl-2 was substantially higher in SCC than in IP and the controls | Stasikowska-Kanicka et al., 2013 [ | |
| Nuclear survivin and immunoexpression of antigen Ki-67 were substantially higher in IP group as compared to the controls | Stasikowska-Kanicka et al., 2013 [ | |
|
| ||
| Wnt proteins | Proteins of Wnt pathway, such as beta-catenin, cyclin D1, and Dvl-1 may have a key role in IP malignancy. Their levels correlate with IP stage | Jung et al., 2015 [ |
|
| ||
| Metallothionein 2A | Protein involved in proliferation and infiltration mechanisms may be associated with pathogenesis of IP and also with increased local malignancy in IP | Starska et al., 2015 [ |
|
| ||
| CCAAT or C/EBPs proteins | Significantly higher amount of C/EBP-alpha expressed upon IP recurrence than in primary tumor | Shabana et al., 2013 [ |
|
| ||
| C/EBP | They may be valuable markers of IP recurrence | Yaun et al., 2015 [ |
|
| ||
| E-Cadherin and | Markers helpful in monitoring of IP transformation into a malignant tumor | Koo et al., 2011 [ |
|
| ||
| Proteins p16, p53, EGFR, and cyclin D1 | Markers potentially helpful in monitoring of IP patients | Lin et al., 2013 [ |
|
| ||
| PLUNC | Elevated expression in IP with multiple recurrence | Tsou et al., 2014 [ |
|
| ||
| SCCA | Elevated level of SCCA correlates with IP, which | Matoušek et al., 2014 [ |
|
| ||
| SCCA2/SCCA1 | Can be helpful to detect SCC malignant transformation in IP patients | Suzuki et al., 2012 [ |